Skip to main content

Table 2 Pharmacokinetics of fosmidomycin and clindamycin analysed by non-compartmental model in patients with acute uncomplicated falciparum malaria. Data are presented as median (95% C.I.) values.

From: Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria

Pharmacokinetic parameters

Fosmidomycin monotherapy (N = 15)

Fosmidomycin + Clindamycin (N = 18)

  

Fosmidomycin

Clindamycin

Cmax (μg/ml)

4.58 (2.32–6.77)

5.86 (2.79–12.52)

7.34 (4.88–12.73)

tmax (hr)

2 (1–4)

2 (1–4)

1 (1–2)

Ctrough-obs (μg/ml)

1.90 (0.92–2.99)

0.40 (0.0–2.01)

1.32 (0.39–3.42)

Cmin-ave (μg/ml)

1.47 (0.06–9.96)

1.06 (0.20–2.98)

0.17 (0.01–0.78)

Cmax-ave (μg/ml)

7.22 (1.52–15.84)

8.67 (4.21–14.23)

6.63 (3.96–9.52)

Css-ave (μg/ml)

3.74 (3.18–12.52)

2.93 (1.97–6.98)

1.91 (1.20–3.06)

Fluctuation

5.1 (1.6–47.6)

10.5 (3.6–40.3)

1.1 (0.7–1.6)

AUC0, t (μg.hr/ml)

22.91 (12.65–33.32)

35.00 (20.41–78.90)

31.80 (15.84–370.67)

AUC0,((μg.hr/ml)

29.7 (25.06–100.16)

39.13 (24.29–85.55)

31.91 (19.28–50.49)

λ Z (/hr

0.201 (0.06–0.48)

0.196 (0.107–0.308)

0.272 (0.156–0.464)

T1/2z (/hr)

3.4 (1.4–11.8)

3.5 (2.2–6.5)

2.6 (1.5–4.4)

VZ/F (l)

211.40 (96.84–823.04)

116.21 (69.94–267.45)a

67.50 (46.56–135-87)

CL/F (l/hr)

40.08 (11.97–47.18)

25.94 (10.74–38.13)b

18.77 (11.77–30.12)

  1. a = Statistically significant difference with monotherapy with p-value = 0.004
  2. b = Statistically significant difference with monotherapy with p-value < 0.0001